Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How AstraZeneca is reformulating durvalumab (Imfinzi) for subcutaneous delivery using Halozyme ENHANZE technology — and what it means for the SC checkpoint inhibitor race.
Article | Rapport A 2026 landscape of advanced nuclear reactor fuel technology: ATF compositions, HALEU supply chains, REMIX recycling, TRISO fuels, and closed fuel cycle strategies.
Article | Rapport AbbVie's Rinvoq (upadacitinib) faces a pivotal 2026: expanding into atopic dermatitis and AS while navigating JAK inhibitor class-wide safety labeling scrutiny.
Article | Rapport Merck's Keytruda faces a 2028 patent cliff. Explore pembrolizumab successor pipeline, fixed-dose combinations, and ADC partnerships shaping the post-cliff strategy.
Article | Rapport A 2026 patent and literature landscape of wearable continuous health monitoring: key technology clusters, top assignees, emerging directions, and strategic implications.
Article | Rapport Capivasertib (AZD5363) targets the PI3K/AKT/PTEN pathway in HR+/HER2- breast cancer. Explore the CAPItello-291 Phase III rationale, IP signals, and combination strategy.
Article | Rapport An overview of tarlatamab's DLL3-targeting BiTE mechanism, the DeLLphi-312 first-line SCLC trial design, and IO + bispecific combination rationale for extensive-stage SCLC.
Article | Rapport Patritumab deruxtecan (HER3-DXd) is reshaping post-EGFR TKI NSCLC treatment. Explore the patent race, clinical data, and Daiichi Sankyo/AstraZeneca strategy.
Article | Rapport Explore the 2026 wearable continuous health monitor technology landscape: key patent trends, R&D signals, and innovation intelligence from PatSnap Eureka.
Article | Rapport LAG-3 combination therapy relatlimab plus nivolumab vs. pembrolizumab in adjuvant melanoma: checkpoint mechanisms, clinical context, and IP landscape analysis.
Article | Rapport TERN-501 is a selective THRβ agonist developed by Terns Pharmaceuticals for MASH. Explore its patent landscape, mechanism, and competitive positioning against resmetirom.
Article | Rapport Icotrokinra (JNJ-2113) is the first oral IL-23 receptor peptide inhibitor in Phase III for psoriasis. Explore J&J's patent strategy and the race to challenge injectable biologics.
Article | Rapport Iptacopan vs. ravulizumab in PNH: how oral Factor B inhibition reshapes complement therapy, hemoglobin endpoints, and the competitive landscape.
Article | Rapport How GSK depemokimab and tezepelumab are reshaping severe asthma treatment beyond eosinophil-high phenotypes — a deep dive into the alarmin axis competitive race.
Article | Rapport How amivantamab redefined EGFR exon 20 insertion NSCLC treatment — and why the HER2 pipeline is racing to replicate that blueprint. Patent and clinical data analysis.